Flossmoor resident and cancer survivor Ann Jackson launched the Center for Food Equity in Medicine at Flossmoor Community ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.
4don MSN
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback